Skip to main content
Eyebrow Nav
  • Connect With Us
  • I'm a Patient
Home
Main navigation
  • About Narcolepsy
    • Pathophysiology
  • Screening & Diagnosis
    • Identifying Narcolepsy
    • Screeners
    • Diagnostic Criteria
    • Diagnostic Process
    • Diagnostic Challenges
  • Comorbidity Risk
    • Cardiovascular Comorbidities
    • Modifiable Risks for CV Disease
    • High Sodium Intake and CV Disease
    • Excess Sodium Intake Impact on Certain Body Systems
    • Psychiatric and Sleep Comorbidities
  • Disease Management
    • Management Considerations
  • Pediatric Patients
    • Burden of Illness
    • Symptoms
    • Clinical Interview
    • Differential Diagnosis
    • Screening
    • Patient and Caregiver Perspectives
  • Stay Connected
    • Connect With Us
    • Sleep Organizations
    • About NarcolepsyLink
  • Resources
    • Expert Clinical Insights
    • Clinical Resources
    • Narcolepsy FAQs
    • Glossary of Terms
Main navigation
  • About Narcolepsy
    • Pathophysiology
  • Screening & Diagnosis
    • Identifying Narcolepsy
    • Screeners
    • Diagnostic Criteria
    • Diagnostic Process
    • Diagnostic Challenges
  • Comorbidity Risk
    • Cardiovascular Comorbidities
    • Modifiable Risks for CV Disease
    • High Sodium Intake and CV Disease
    • Excess Sodium Intake Impact on Certain Body Systems
    • Psychiatric and Sleep Comorbidities
  • Disease Management
    • Management Considerations
  • Pediatric Patients
    • Burden of Illness
    • Symptoms
    • Clinical Interview
    • Differential Diagnosis
    • Screening
    • Patient and Caregiver Perspectives
  • Stay Connected
    • Connect With Us
    • Sleep Organizations
    • About NarcolepsyLink
  • Resources
    • Expert Clinical Insights
    • Clinical Resources
    • Narcolepsy FAQs
    • Glossary of Terms
  • Connect With Us
  • I'm a Patient
Image
Graph

The prevalence of certain comorbidities is higher in patients with narcolepsy compared with matched controls3-5

SEE THE DATA

Image
Venn diagram

Some risk factors for cardiovascular disease in the general population are modifiable with changes to the management plan6-15

DISCOVER THE RISKS

Image
interactive infographic image
Image
carousel slide 2
Image
carousel slide 3
Image
carousel slide 4

Certain comorbidities, including cardiovascular (CV) conditions, occur more frequently in patients with narcolepsy compared with matched controls.3-5 Some common risk factors for CV disease are modifiable, including sodium intake.7

Learn more about the
impact of high sodium

Find answers to your questions about narcolepsy, including diagnosis, risk factors for comorbidities, and patient lifestyle modifications.

Watch expert interviews

Learn more about the complexities, burden, and potential long-term health implications of narcolepsy for your patients.

Listen to the expert presentations

Sleep specialists discuss how recent research has led to a more comprehensive, long-term management approach to narcolepsy.

Download the white paper

  1. Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benefits. 2017;10(5):233-241.
  2. Flores NM, Villa KF, Black J, Chervin RD, Witt EA. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12(3):401-407.
  3. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488-492.
  4. Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13-18.
  5. Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14-18.
  6. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018;71(6):e136-e139] [published correction appears in Hypertension. 2018;72(3):e33]. Hypertension. 2018;71(6):1269-1324.
  7. Jackson SL, King SM, Zhao L, Cogswell ME. Prevalence of excess sodium intake in the United States—NHANES, 2009-2012. MMWR Morb Mortal Wkly Rep. 2016;64(52):1393-1397.
  8. Benjamin EJ, Muntner P, Alonso A, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.
  9. Lloyd-Jones DM, Hong Y, Labarthe D, et al.; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
  10. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases—incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29(4):611-618.
  11. Quan SF. Sleep disturbances and their relationship to cardiovascular disease. Am J Lifestyle Med. 2009;3(1 suppl):55s-59s.
  12. Centers for Disease Control and Prevention. Sleep and sleep disorders: Sleep and Chronic Disease. https://www.cdc.gov/sleep/about_sleep/chronic_disease.html. Last reviewed August 8, 2020. Accessed April 30, 2021.
  13. McAlpine CS, Kiss MG, Rattik S, et al. Sleep modulates haematopoiesis and protects against atherosclerosis.  Nature.  2019;566(7744):383-387.
  14. Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy.  PLoS One.  2012;7(6):e38977.
  15. Grimaldi D, Calandra-Buonaura G, Provini F, et al. Abnormal sleep-cardiovascular system interaction in narcolepsy with cataplexy: effects of hypocretin deficiency in humans.  Sleep.  2012:35(4):519-528.
Image
Jazz Pharmaceuticals logo

Terms of Use

Connect With Us

Privacy Statement

Site Map

About NarcolepsyLink

NarcolepsyLink® is sponsored by Jazz Pharmaceuticals

©2026 Jazz Pharmaceuticals, Inc.

US-SLE-2100121 REV1224

You are now leaving NarcolepsyLink.com

Click "OK" to continue or "CANCEL" to return to
NarcolepsyLink.com.

Cancel OK

You are now leaving NarcolepsyLink.com

You will be directed to a website for a treatment option indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.

Cancel Continue

Are You a Healthcare Professional?

The information on the NarcolepsyLink website is intended for healthcare professionals only.

NO YES